Arax Advisory Partners
RAPP icon

Arax Advisory Partners’s Rapport Therapeutics RAPP Stock Holding History

Arax Advisory Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25K Buy
+54
New +$1.98K ﹤0.01% 4790
2026
Q1 		– Sell
-500
Closed -$15.2K – 4418
2025
Q4 		$15.2K Sell
500
-64
-11% -$1.77K ﹤0.01% 2264
2025
Q3 		$16.8K Buy
+564
New +$10.1K ﹤0.01% 2355

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Sofinnova Investments
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Arax Advisory Partners's RAPP Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 54 shares worth $2.25K. The stake represents ﹤0.01% of the portfolio and ranks #4790 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in RAPP as recently as Q4 2025.

Arax Advisory Partners first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. The position peaked at $16.8K in Q3 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Arax Advisory Partners held 54 shares of Rapport Therapeutics worth $2.25K as of Q2 2026.
  • Rapport Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4790 holding.
  • Arax Advisory Partners first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Rapport Therapeutics position peaked at $16.8K in Q3 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.